SEC Form 10-Q filed by Rein Therapeutics Inc.
$RNTX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/22/2025 | $10.00 | Buy | H.C. Wainwright |
| 1/28/2025 | $8.00 | Buy | Rodman & Renshaw |
AUSTIN, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that a new preprint has been posted to medRxiv describing clinical and translational findings from an inhaled, dose-escalation study of Rein's lead drug candidate, LTI-03, in idiopathic pulmonary fibrosis (IPF). The preprint, titled "Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study," was authored by an international team of investigators, including Philip L. Molyneaux, MD, Nikhil A. Hi
FDA lifts clinical hold following review of Company's Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites.Early data suggests that LTI-03 may not only slow fibrosis but also promote lung healing. AUSTIN, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the U.S. Food and Drug Administration (FDA) has lifted the full clinical hold on the Company's Phase 2 "RENEW" trial evaluating LTI-03 in patient
EMA approval covers study sites in Germany and Poland as part of the Company's global Phase 2 RENEW trialTrial will evaluate LTI-03, a first-in-class therapy designed to both reduce lung scarring and promote repair AUSTIN, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has received authorization from the European Medicines Agency (EMA) to initiate the Company's Phase 2 "RENEW" clinical trial of its lead candidate, LTI-03, for the treatment of idiopathic pulmona
H.C. Wainwright initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $10.00
Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00
8-K - Rein Therapeutics, Inc. (0001420565) (Filer)
8-K - Rein Therapeutics, Inc. (0001420565) (Filer)
8-K - Rein Therapeutics, Inc. (0001420565) (Filer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
3 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)